Skip to main content

Carey Kernodle Anders

Professor of Medicine
Medicine, Medical Oncology
Box 3381, Seeley Mudd Building, Durham, NC 27710
Dept of Medicine, Durham, NC 27710

Current Appointments & Affiliations


Professor of Medicine · 2020 - Present Medicine, Medical Oncology, Medicine
Chief, Division of Medical Oncology · 2021 - Present Medicine, Medical Oncology, Medicine
Member of the Duke Cancer Institute · 2019 - Present Duke Cancer Institute, Institutes and Centers

In the News


Published August 29, 2022
When Cancer Spreads to the Brain and Spine

View All News

Recent Publications


Genomic and immune profiling of breast cancer brain metastases.

Journal Article Acta Neuropathol Commun · May 12, 2025 BACKGROUND: Brain metastases (BrM) arising from breast cancer (BC) are an increasing consequence of advanced disease, with up to half of patients with metastatic HER2 + or triple negative BC experiencing central nervous system (CNS) recurrence. The genomic ... Full text Link to item Cite

Triple Negative Breast Cancer and Brain Metastases.

Journal Article Clin Breast Cancer · December 2023 The treatment of metastatic breast cancer (MBC) has improved over the past decade, however prognosis continues to be mitigated by the fact that about 1 in 5 patients with MBC will develop brain metastases (BrM) during their metastatic disease course. 1 Thi ... Full text Link to item Cite

Systemic Therapy Approaches for Breast Cancer Brain and Leptomeningeal Metastases.

Journal Article Curr Treat Options Oncol · October 2022 Brain metastasis arising from breast cancer is associated with a poor prognosis. Various systemic chemotherapy and targeted therapies which are effective against breast cancer often fail to provide benefits against brain metastasis. This is mainly due to l ... Full text Link to item Cite
View All Publications

Recent Grants


Prospective Registry of Trastuzumab Deruxtecan in Patients with Active/Progressive HER2-Positive Breast Cancer Brain Metastases

ResearchPrincipal Investigator · Awarded by Johns Hopkins University · 2025 - 2030

DATO-BASE: A phase 2 trial of DATOpotamab-deruxtecan for breast cancer Brain metAstaSEs

Clinical TrialPrincipal Investigator · Awarded by Dana-Farber Cancer Institute · 2024 - 2029

View All Grants

Education, Training & Certifications


East Carolina University, Brody School of Medicine · 2002 M.D.